test-story
Partnering - Immunology
Novartis is committed to transforming immunology by investing in breakthrough science to address the highest unmet needs. Leveraging diverse platforms like cell and gene therapy, small molecule degraders, multispecific biotherapeutics, Novartis develops therapies that target the root causes of immune diseases. As a market leader in deal-making, Novartis partners with innovators to bring game-changing solutions to patients.
Novartis in Society
Published from 2021 to 2024, the Novartis in Society Integrated Report covered our business, strategy and performance, including progress against our environmental, social and governance targets. It superseded the Novartis in Society ESG report (formerly our Corporate Responsibility Report), which was published until 2020.
Novartis In Society Integrated Report: English (PDF 5.0 MB) | Deutsch (PDF 4.7 MB)
Novartis In Society Integrated Report: English (PDF 8.4 MB) | Deutsch (PDF 7.2 MB)
Novartis In Society Integrated Report: English (PDF 8.8 MB) | Deutsch (PDF 7.8 MB)
Novartis In Society Integrated Report: English (PDF 7.7 MB) | Deutsch (PDF 7.7 MB)